Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

Fig. 1

Histone deacetylase inhibitors suppressed proliferation of anaplastic thyroid cancer (ATC) and papillary thyroid carcinoma (PTC) cell lines. Cell viability and proliferation assays demonstrated that HNHA caused the greatest inhibition of thyroid cancer cell proliferation in SNU-80 ATC (a and b) and SNU-790 PTC cells (c and d). TSA, trichostatin A; SAHA, suberoylanilide hydroxamic acid. Data points indicate the mean % of the value observed in the solvent-treated control. All tests were repeated three times and the data symbolize the mean ± standard deviation. SNU-80 and SNU-790 cells were treated for 24 h with the expressed concentrations of HNHA (e) or with 15 μM HNHA for the indicated time-periods (f) prior to isolation of total protein and evaluation of histone H3 and α-tubulin acetylation by immunoblotting. *P < 0.05 vs. Control, **P < 0.01 vs. Control, ***P < 0.005 vs. Control

Back to article page